Company intelligence / Profile preview

ENG

Boston, Massachusetts, United Statesengene.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

enGene is a clinical-stage biotechnology company focused on developing next-generation non-viral gene therapies using its proprietary Dually Derivatized Chitosan (DDX) platform. The company's lead program, detalimogene voraplasmid (EG-70), is currently in a pivotal Phase 2 study for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). By utilizing a non-viral delivery system, enGene aims to provide localized, durable expression of therapeutic proteins directly to mucosal tissues, potentially offering a safer and more accessible alternative to viral-based gene therapies. The company is headquartered in Montreal, Canada, with significant operations in Boston, Massachusetts.

Therapeutic areas: Oncology
Modalities: Gene therapyNon-viral gene therapyPlasmid DNANanoparticle
Industry: Biotech

Beyond the preview

Go deeper on ENG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENG.

Explore the full profile